23:28:30 EDT Thu 16 May 2024
Enter Symbol
or Name
USA
CA



T:GUD - KNIGHT THERAPEUTICS INC. - http://www.gud-knight.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GUD - T  0.86.12·6.191.06.14+0.040.772.64363856.17  6.18  6.076.22  4.3516:00:00May 0915 min RT 2¢
TSX - T0.86.12·6.191.06.14+0.040.734.22052096.17  6.17  6.086.22  4.3516:00:0015 min
NEO ATS - U 6.13+0.030.52.314136.14  6.15  6.0815:50:0715 min
Alpha - A 6.16+0.061.06.137176.10  6.17  6.0815:43:0215 min
Pure - P 6.16+0.061.00.4276.13  6.16  6.1315:36:4115 min
Chi-X - X 6.15+0.050.84.426346.11  6.17  6.0815:36:4115 min
CX2 - H 6.18+0.081.31.0666.07  6.18  6.0715:33:5315 min
CXD - D 6.08-0.02-0.30.63126.08  6.08  6.0811:19:2215 min
TriAct - M 6.1023.614287    Sep 11-2015 min

Recent Trades - Last 10 of 385
Time ETExPriceChangeVolumeBuyerSellerMarkers
16:00:00T6.140.041001 Anonymous79 CIBCKQ
16:00:00T6.140.041001 Anonymous79 CIBCKQ
16:00:00T6.140.04153 Morgan Stanley7 TD SecQ
16:00:00T6.140.0411 Anonymous7 TD SecQ
16:00:00T6.140.04307 TD Sec2 RBCQ
15:59:54T6.120.0220080 National Bank1 AnonymousK
15:59:51T6.120.04317 TD Sec53 Morgan Stanley
15:59:50T6.140.041001 Anonymous7 TD SecK
15:59:20T6.120.0210080 National Bank53 Morgan StanleyK
15:58:32T6.120.0210080 National Bank53 Morgan StanleyK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-05-09 13:13C:GUD6.10SEDAR Interim MD & ASEDAR Interim MD & A
2024-05-09 12:21C:GUD5.92News ReleaseKnight Therapeutics loses $4.54-million in Q1
2024-05-09 12:06C:GUD5.92News ReleaseKnight signs Jornay PM distribution deal with Ironshore
2024-05-09 07:52C:GUD5.92SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-05-09 07:52C:GUD5.92SEDAR Interim MD & ASEDAR Interim MD & A
2024-05-08 19:46C:GUD5.92News ReleaseKnight Therapeutics holders approve all matters at AGM
2024-05-02 11:08C:GUD5.77News ReleaseKnight Therapeutics to release Q1 2024 results May 9
2024-03-27 08:10C:GUD5.44SEDAR Annual ReportSEDAR Annual Report
2024-03-22 07:58C:GUD5.27In the NewsGlobe says Knight seen "as a good long-term investment"
2024-03-21 13:42C:GUD5.23SEDAR MD & ASEDAR MD & A
2024-03-21 10:45C:GUD5.39News ReleaseKnight Therapeutics loses $16.83-million in 2023
2024-03-21 07:50C:GUD5.39SEDAR Annual Information FormSEDAR Annual Information Form
2024-03-21 07:50C:GUD5.39SEDAR MD & ASEDAR MD & A
2024-03-21 07:45C:GUD5.39SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2024-03-14 08:26C:GUD5.28News ReleaseKnight Therapeutics to release 2023 results March 21
2024-03-07 07:52C:GUD5.51In the NewsGlobe says Knight Therapeutics kept at "outperform"
2024-02-29 12:43C:GUD5.55News ReleaseKnight Therapeutics rolls out Minjuvi in Brazil
2024-02-21 17:53C:GUD5.41News ReleaseKnight applies for fostamatinib marketing nod in Brazil
2024-02-06 11:27C:GUDNews ReleaseKnight Therapeutics rolls out Bijuva capsules in Canada
2024-01-25 10:34C:GUD5.51News ReleaseKnight Therapeutics licenses IPX203 from Amneal